Skip to main content
SpringerLink
Log in

Using patient DNA to optimize therapy in heart failure patients: a move toward perfection

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vesell ES (1989) Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 41:535–552

    Article  CAS  PubMed  Google Scholar 

  2. Kalow W, Tang BK, Endrenyi L (1998) Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8:283–289

    Article  CAS  PubMed  Google Scholar 

  3. Evans WE, McLeod HL (2003) Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 348:538–549

    Article  CAS  PubMed  Google Scholar 

  4. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491

    Article  CAS  PubMed  Google Scholar 

  5. Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9–39

    Article  CAS  PubMed  Google Scholar 

  6. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529–537

    Article  PubMed  Google Scholar 

  7. Kalow W (1956) Familial incidence of low pseudocholinesterase level. Lancet 2:576

    Article  Google Scholar 

  8. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667–1671

    Article  CAS  PubMed  Google Scholar 

  9. Sachidanandam R, Weissman D, Schmidt SC et al (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928–933

    Article  CAS  PubMed  Google Scholar 

  10. International hapmap consortium expands mapping effort. National Institutes of Health; National Human Genome Research Institute, 2005. http://www.genome.gov/13014173. Accessed 7 Feb 2005

  11. Wang WY, Barratt BJ, Clayton DG, Todd JA (2005) Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6:109–118

    Article  CAS  PubMed  Google Scholar 

  12. Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6:95–108

    Article  CAS  PubMed  Google Scholar 

  13. Yu J, Shannon WD, Watson MA, McLeod HL (2005) Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 11:2053–2062

    Article  CAS  PubMed  Google Scholar 

  14. Gerhold DL, Jensen RV, Gullans SR (2002) Better therapeutics through microarrays. Nat Genet 32(Suppl):547–551

    Article  CAS  PubMed  Google Scholar 

  15. Merrick BA, Bruno ME (2004) Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Curr Opin Mol Ther 6:600–607

    CAS  PubMed  Google Scholar 

  16. Drysdale CM, McGraw DW, Stack CB et al (2000) Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97:10483–10488

    Article  CAS  PubMed  Google Scholar 

  17. Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, Liggett SB (2004) Polymorphisms of cardiac presynaptic α2C adrenergic receptors: diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci USA 101:13020–13025

    Article  CAS  PubMed  Google Scholar 

  18. Pont-Kingdon G, Lyon E (2005) Direct molecular haplotyping by melting curve analysis of hybridization probes: beta 2-adrenergic receptor haplotypes as an example. Nucleic Acids Res 33:e89

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by the NIH Pharmacogenetics Research Network (U01 GM63340).

Author information

Authors and Affiliations

  1. UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Division of Hematology and Oncology, and the Lineberger Comprehensive Cancer Center, University of North Carolina, Campus Box 7360, Chapel Hill, NC, 27599, USA

    Howard L. McLeod

Authors
  1. Howard L. McLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard L. McLeod.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLeod, H.L. Using patient DNA to optimize therapy in heart failure patients: a move toward perfection. Heart Fail Rev 15, 183–185 (2010). https://doi.org/10.1007/s10741-009-9150-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-009-9150-1

Keywords

Search

Navigation